Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the firm's investments. In Fund I, she led the investments in Medicago, which was acquired by Mitsubishi Tanabe for $357 M in 2013, and Zymeworks, which went public in 2017. She was also a board observer in Enobia, which was acquired by Alexion in 2012 for >$1B. In Fund II, Shermaine led the investments in Vaxcyte, which became Fund II’s top success story, and IMV and Phenomic AI. Shermaine is an active board director of Phenomic AI and PSCorp (formerly Phemi Systems). She also served until recently on the boards of BIOTECanada for 7 years and TIAP (formerly MaRS Innovation) for 4 years.

Before joining CTI LSF, Shermaine was the Senior VP at DRI Capital Inc., closing 12 transactions totaling over $200M in investments. Before DRI Capital Inc., Shermaine held faculty positions at the NYU School of Medicine and Public Health Research Institute (PHRI) and was on PHRI’s Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious disease for ten years. Shermaine holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine and an MBA from the University of Toronto and is a CFA Society of Toronto member.

‍